Welcome to our dedicated page for NeuroOne Medical Technologies Corporation news (Ticker: NMTC), a resource for investors and traders seeking the latest updates and insights on NeuroOne Medical Technologies Corporation stock.
NeuroOne Medical Technologies Corporation (symbol: NMTC) is a cutting-edge medical technology company based in Eden Prairie, Minnesota. The company specializes in the development and commercialization of innovative thin-film electrode technology designed for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, brain stimulation, and ablation solutions. These technologies are particularly beneficial for patients suffering from a variety of brain-related disorders, including epilepsy, Parkinson's disease, dystonia, and essential tremors.
NeuroOne's core business revolves around creating comprehensive neuromodulation solutions that integrate cEEG and sEEG recording, monitoring, brain stimulation, and ablation. This focus has led to notable advancements such as the Evo® sEEG system, which is the first FDA-cleared thin-film sEEG-guided RF system capable of both recording electrical activity and ablating nervous tissue, with the added benefit of temperature control.
The company is actively involved in various exciting projects and partnerships. One of their key initiatives is the Drug Delivery Program, which is expected to achieve several important milestones in the near future. Additionally, NeuroOne is continuously enhancing its product portfolio to better serve its target patient population.
Financially, NeuroOne has provided promising updates for the second quarter of the fiscal year 2024. The company’s recent business highlights include significant progress in their OneRF™ Ablation System and Spinal Cord Stimulation Program. Investors and interested parties can access more detailed financial results and updates through their quarterly conference calls and webcasts.
For more information or to get in touch with NeuroOne, please contact them at 800-631-4030 or email ir@nmtc1.com.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced a proposed underwritten public offering of its common stock, intending to use the net proceeds for working capital and general corporate purposes. The offering includes a 30-day option for the underwriter to purchase an additional 15% of the shares sold. The offering is subject to market conditions and may not be completed as planned. Craig-Hallum Capital Group acts as the sole underwriter. The public offering is made under an effective shelf registration statement as filed with the SEC on June 14, 2021.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced the successful completion of an animal feasibility study for its Evo® ablation electrode, conducted at T3 Labs and Georgia Tech under Dr. Robert Gross. The study demonstrated the ability to record brain activity and ablate tissue, aimed at improving treatment for neurological disorders. The Evo ablation electrode, pending FDA clearance, could allow dual procedures in one hospital visit, enhancing patient care and reducing costs. The company also noted its partnership with RBC Medical for radiofrequency hardware development.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its participation in the H.C. Wainwright 23rd Annual Global Investment Conference, taking place virtually from September 13-15, 2021. The presentation will be available on-demand starting September 13. Management will also conduct one-on-one investor meetings during the event. NeuroOne focuses on innovative surgical solutions for neurological disorders, having received FDA clearance for its Evo cortical and sEEG electrode technologies. The company aims to improve patient outcomes and reduce costs.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced FDA 510(k) clearance for its Evo sEEG Electrode technology, designed for temporary use in recording, monitoring, and stimulating subsurface brain signals. This product is the second FDA-cleared device for the company, tapping into a $100 million market for brain mapping. NeuroOne aims to expand sEEG labeling for longer-term use and develop therapeutic electrodes for chronic conditions, with an estimated addressable market between $500 million and $6 billion. The company anticipates being launch-ready by the end of 2021.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) was featured on Cheddar News, discussing advancements in their brain implant technology aimed at improving treatment for neurological disorders. CEO Dave Rosa highlighted the unique high-definition capabilities of their sEEG electrodes, offering 900 contact points compared to traditional electrodes, which enhance precision and clarity. The company aims to integrate multiple functions into one device, reducing the need for multiple surgeries. NeuroOne's partnerships with major medical entities enhance its development efforts, focusing on conditions like epilepsy and Parkinson's disease.
NeuroOne Medical Technologies Corporation (NMTC) has partnered with RBC Medical Innovations to develop a proprietary radiofrequency generator, aiming to innovate seizure treatment. This partnership combines diagnostic and therapeutic functions into a single electrode, simplifying the process for patients with epilepsy or brain tumors. This advancement is set to save time and costs while potentially improving outcomes. The market for this innovation is projected to exceed $100M. Completion of the project is anticipated by late 2022, pending regulatory clearance.
NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) announced its third quarter financial results for fiscal 2021, achieving product revenue of $40,000 and collaboration revenue of $17,000, a notable increase from zero revenue in the same quarter last year. Operating expenses totaled $3.0 million, with a net loss of $3.0 million, improved from a net loss of $7.1 million in the prior year. The company completed its first human use of the Evo Cortical electrode at Mayo Clinic and closed a $12.5 million private placement. NeuroOne is on track for further product launches and has uplisted to Nasdaq.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will host a conference call on August 13, 2021, at 9:00 AM ET to discuss its financial results for the third quarter ended June 30, 2021. The company focuses on innovative surgical solutions for neurological disorders. Notably, NeuroOne successfully achieved its first performance milestone in a partnership with Zimmer Biomet, securing exclusive global distribution rights for its Evo™ patented electrode technology. The company has received FDA clearance for this technology in November 2019.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) announced its participation in the Alliance Global Partners Virtual MedTech Summer Conference on July 29, 2021. The event will feature one-on-one virtual meetings between investors and management. NeuroOne focuses on developing advanced EEG recording and ablation solutions for neurological disorders like epilepsy and Parkinson's disease. The company recently achieved a key milestone in its distribution agreement with Zimmer Biomet, further enhancing its market position.
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) will present at the Access to Giving Virtual Conference on July 15, 2021, at 2 p.m. ET. The conference aims to connect companies with investors for fundraising opportunities. NeuroOne focuses on innovative solutions for neurological disorders, including epilepsy and Parkinson's disease, leveraging patented electrode technology. The company previously achieved a performance milestone with Zimmer Biomet and received FDA clearance for its Evo cortical technology in November 2019. For more details, visit n1mtc.com.
FAQ
What is the current stock price of NeuroOne Medical Technologies Corporation (NMTC)?
What is the market cap of NeuroOne Medical Technologies Corporation (NMTC)?
What does NeuroOne Medical Technologies Corporation focus on?
Where is NeuroOne Medical Technologies Corporation based?
What disorders does NeuroOne's technology address?
What is the Evo® sEEG system?
What are some of NeuroOne's current projects?
How can I contact NeuroOne Medical Technologies Corporation?
What recent financial updates has NeuroOne provided?
What type of medical technology does NeuroOne specialize in?
What is the significance of the FDA clearance for NeuroOne's technology?
Where can I find more detailed financial results and updates about NeuroOne?
